|
Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Novartis |
Research Funding - AstraZeneca; Bristol-Myers Squibb |
|
|
Honoraria - Dava Oncology |
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Genentech; Merck; Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; pfizer; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen Oncology; Lilly; Merck; Syndax |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
Other Relationship - Bristol-Myers Squibb; merck |